Wells Fargo & Company Aeterna Zentaris Inc. Transaction History

Wells Fargo & Company

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$0.36 - $0.77 $1,440 - $3,080	-4,000 Reduced 44.44%	5,000 $2,000
Q2 2021 Aug 16, 2021	SELL	$0.83 - $1.14 $8,300 - $11,399	-10,000 Reduced 52.63%	9,000 $8,000
Q1 2021 May 13, 2021	BUY	$0.51 - $3.34 $7,140 - $46,760	14,000 Added 280.0%	19,000 $22,000
Q2 2020 Aug 13, 2020	BUY	$0.45 - $1.2 $1,890 - $5,040	4,200 Added 525.0%	5,000 $4,000
Q1 2020 May 14, 2020	BUY	$0.42 - $1.44 $336 - $1,152	800 New	800 $0

Ticker AEZS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 4,855,880
Market Cap $19.4M
Description
Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is macimorelin, an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult grow...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.